KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $485.4 million.

  • Sarepta Therapeutics' Current Deferred Revenue rose 28224.03% to $485.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $485.4 million, marking a year-over-year increase of 28224.03%. This contributed to the annual value of $130.3 million for FY2024, which is 15836.24% up from last year.
  • Sarepta Therapeutics' Current Deferred Revenue amounted to $485.4 million in Q3 2025, which was up 28224.03% from $395.4 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Current Deferred Revenue high stood at $485.4 million for Q3 2025, and its period low was $22.5 million during Q3 2023.
  • In the last 5 years, Sarepta Therapeutics' Current Deferred Revenue had a median value of $89.2 million in 2021 and averaged $121.9 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Current Deferred Revenue tumbled by 7479.49% in 2023, and later skyrocketed by 46459.94% in 2024.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Current Deferred Revenue stood at $89.2 million in 2021, then changed by 0.0% to $89.2 million in 2022, then tumbled by 43.51% to $50.4 million in 2023, then surged by 158.36% to $130.3 million in 2024, then surged by 272.69% to $485.4 million in 2025.
  • Its Current Deferred Revenue stands at $485.4 million for Q3 2025, versus $395.4 million for Q2 2025 and $44.9 million for Q1 2025.